- Home
- FBK vs HCM Comparison
FBK vs HCM Comparison
Compare FBK & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBK | HCM |
|---|---|---|
| Founded | 1906 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | FBK | HCM |
|---|---|---|
| Price | $54.32 | $13.33 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $64.50 | $13.75 |
| AVG Volume (30 Days) | ★ 262.9K | 26.7K |
| Earning Date | 04-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.72 | $20.60 |
| Revenue Next Year | $7.21 | $15.62 |
| P/E Ratio | $22.10 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.29 | $13.06 |
| 52 Week High | $62.37 | $19.50 |
Technical Indicators
Market Signals| Indicator | FBK | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 33.51 |
| Support Level | $52.27 | $13.08 |
| Resistance Level | $54.84 | $15.59 |
| Average True Range (ATR) | 1.35 | 0.44 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 41.78 | 8.24 |
Price Performance
Historical ComparisonAbout FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.